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Abstract
In recent years there has been renewed interest in colistin for
the treatment of infections by multidrug-resistant Gram-negative
bacteria, causing concern that increasing use may be accompanied
by the emergence of resistance. This is a retrospective cohort
study of colonization and infection by colistin-resistant (CR)
gram-negative bacteria in critically ill patients. Colonization data
were based on surveillance culture results. Among 150 patients,
78 (52%) were colonized by CR Gram-negative bacteria. Among
them, 30 (20%) were colonized by Klebsiella pneumoniae isolates
and 51 (34%) were colonized by intrinsically resistant to colistin
(CIR) enterobacteriaceae. Seven cases of infection were caused
by CR K. pneumoniae and 12 cases by CIR strains. The main risk
factor for colonization by CR pathogens was colistin treatment.
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In the last decade the increased incidence of infections by
multidrug-resistant Gram-negative bacteria (MDR-GNB),
especially in critically ill patients, restored colistin, a
neglected antimicrobial, to clinical practice, as it is one of the
very few and in some cases the only antimicrobial with activ-
ity against pathogens such as carbapenem-resistant Acineto-
bacter spp and carbapenemase producing Pseudomonas
aeruginosa and Klebsiella pneumoniae [1]. However, there is
concern that selective pressure due to extensive colistin use
may lead to the emergence of resistance. In addition, super-
infection with pathogens intrinsically resistant to colistin
(CIR), including Proteus, Providencia, Serratia and Morganella
species, may also be a matter of concern.
This retrospective cohort study describes data regarding
colonization and infection by colistin-resistant enterobacteri-
aceae and investigates associated risk factors in the general
Intensive Care Unit (ICU) of University General Hospital
Attikon, a 700-bed hospital in Athens during a 3-year period
(November 2003 to December 2006). During the study per-
iod, the size of the ICU increased gradually from four to 12
beds by the end of 2006. All patients with a length of stay of
>7 days and at least two available consecutive surveillance
culture specimens were included. Microbiological data from
surveillance cultures and clinical samples were used. Blood-
stream infection, ventilator-associated pneumonia and skin
and soft tissue infection were diagnosed according to the
deﬁnitions adopted by CDC/NHSN [2].
Twice weekly active surveillance of patient ﬂoras (faecal,
urinary and respiratory) was performed. All specimens were
cultured on McConkey agar plates containing antibiotics
(ceftazidime, imipenem and piperacilline/tazobactam) so as to
expedite detection of resistant pathogens [3]. Growth in any
of the above media during the ﬁrst 24 h of incubation indi-
cated the presence of resistant strains. Isolates displaying a
10-lg colistin disk inhibition zone of <14 mm were subse-
quently evaluated for colistin resistance by the E-test method
[4]. All isolates exhibiting an MIC ‡4 lg/dL were considered
resistant according to the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST) [5].
Using repetitive chromosomal elements polymerase chain
reaction (REP-PCR), susceptible and resistant K. pneumoniae
isolates from the same patient and site were compared. In
cases of isolation of a resistant isolate in a patient previously
colonized by a susceptible isolate of the same clone, it was
assumed that a resistance mutation had developed. In all
other cases horizontal transmission of the resistant isolate
was assumed to have occurred.
Data were analysed with SPSS version 16.0 (SPSS, Chi-
cago, IL, USA). Categorical variables were compared by the
Fisher’s exact test and scalar variables by the non-parametric
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Mann–Whitney U-test. Differences with p-value < 0.05 were
considered statistically signiﬁcant. Variables analysed for cor-
relation with colonization by colistin resistant K. pneumoniae
(CRKP) by univariate analysis included age, gender, APACHE
II score on admission to the ICU, length of stay in the ICU
and administration of piperacilline/tazobactam, carbapenem
or colistin. Variables with p-value < 0.1 were included in
stepwise multivariate logistic regression analysis.
During the study period 150 patients (94 males and 56
females) were enrolled with a median age of 72 years (range
14–89). The median length of stay was 32 days (IQR 42) and
median APACHE was 18 (IQR 10). Ninety-four patients
(63%) received colistin, 88 (94%) of whom received it in
combination with either piperacillin/tazobactam or a carbape-
nem.
In total 445 Gram-negative microorganisms were isolated
from 150 patients (Table 1). Seventy-eight (52%) patients
were colonized by CR pathogens and 30 (20%) of them were
CRKP. Thirteen of these patients have been included in a
previous study describing the ﬁrst outbreak of CRKP in
Greece [6]. The site of the initial isolation of CRKP was a
stool in 15 (50%) cases, respiratory secretions in eight (27%)
and urine in seven (23%). The most frequent colonization
site of CR pathogens was the rectum in 22 cases (75%) for
CRKP and the respiratory tract for P. aeruginosa and
A. baummanni (two and three cases, respectively).
Among patients colonized by CRKP, three were already
colonized on admission while the rest were colonized during
their stay in the ICU. Only one patient was colonized by
CRKP during hospitalization without having previously
received colistin. CRKP isolates were assigned to 20 distinct
clones by REP-PCR methodology. Among them, 15 devel-
oped during treatment with colistin in the study ICU, while
the rest were transferred from other hospitals.
Among 30 patients colonized by CRKP, 27 (90%) had
received colistin (p < 0.001; OR, 6.98; 95% CI, 2.0–24.3).
Among 94 patients exposed to colistin, 27 (28.7%) were col-
onized by CRKP. Patients colonized by CRKP had received
colistin for a median of 20.0 days, compared with 14.5 days
for patients not colonized by CRKP (p 0.048). Results of the
univariate and multivariate analysis of risk factors for coloni-
zation by CRKP are summarized in Table 2.
Fifty-one (34%) of the patients were colonized by CIR
pathogens (Table 1). Among them, nine patients were colo-
nized by two and two were colonized by three CIR patho-
gens. Thirty-two (64%) of them had been exposed to colistin
(p NS), with median length of treatment with colistin
26.0 days, compared with 14 days in patients exposed to
colistin but not colonized by CIR pathogens (p 0.02). Twelve
(24%) of these patients were simultaneously colonized by
CRKP. Infections by CIR pathogens developed in 12 (24%)
patients. All cases of infection occurred in patients previously
TABLE 1. Colonization, infection and mortality by colistin-resistant (CR) pathogens (VAP, ventilator associated pneumonia;
BSI, blood stream infection)
Colonization,
No (%)
Infection All-cause
mortality,
No (%)VAP BSI Other Total
CR pathogen
Klebsiella pneumoniae 30 (20) 1 5 1 7 (23) 6 (86)
Pseudomonas aeruginosa 2 (1) 0 0
Acinetobacter baumanii 4 (3) 0 0
Enterobacter aerogenes 3 (2) 1 1 (33) 1 (100)
Escherichia coli 2 (1) 0 0
CIR pathogens
Serratia marcescens 16 (13) 3 3 (18) 2 (67)
Providencia stuartii 8 (5) 1 1 (13) 1
Proteus mirabilis 23 (15) 2 3 5 (22) 2 (40)
Morganella morganii 16 (11) 3 3 (19) 3 (100)
TABLE 2. Univariate and multivariate analysis of risk factors for colonization by CR Klebsiella pneumoniae
Colonized
by CRKP
Not colonized
by CRKP
Univariate
analysis
Multivariate
analysis
Odds
ratio
Age, median (range) 68 (22–86) 72 (14–89) NS
Gender (female/male) 11/19 54/66 NS
APACHE II score, median (IQR) 19.5 (11.75) 18.0 (10) NS
Colistin treatment (%) 27 (90) 67 (56) <0.001 <0.001 5.2
Carbapenem treatment (%) 23 (77) 81 (68) NS
Piperacillin/tazobactam treatment (%) 16 (53) 77 (64) NS
Median length of stay in ICU, days (IQR) 65 (61) 26 (32) <0.001 NS
Median duration of colistin treatment, days (IQR) 20.0 (17) 14.5 (23) 0.048
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colonized by the respective pathogens and having received
treatment by colistin (p 0.003; OR, 1.7).
Although colistin resistance has been considered a rare
occurrence [7], increasing colistin use has been followed by
reports describing clinical isolates of colistin-resistant GNB.
One of the ﬁrst refers to a multiclonal cluster of CRKP col-
onization and infection in a retrospective study based on the
surveillance of faecal and bronchial ﬂora in critically ill
patients [6]. In another study 41 colistin-resistant isolates
were described [8]. Similarly to the present results, in the
latter study the main risk factor for colistin resistance was
the use of colistin. However, the lack of surveillance data
and of genotypic analysis precluded any conclusions about
the way these strains were acquired. In two additional stud-
ies from Greece and one from the United States a total of
25 patients colonized or infected by KPC producing K. pneu-
moniae resistant to colistin have been described. However, in
all these studies the isolates were clonally related, suggesting
horizontal transmission [9–11]. Non-clonal emergence of
CRKP has been described in one study including 15 isolates
from patients with bacteraemia [12]. This is the ﬁrst study
that included both colonization and infection data in a cohort
of critically ill patients as well as genotypic analysis of the iso-
lates, permitting the distinction between horizontal transmis-
sion and development of resistance.
Genotypic analysis of the isolates revealed that the major-
ity of the CRKP isolates belonged to different clones. This
ﬁnding indicates that resistance emerged through selection
pressure rather than spread by horizontal transmission. This
observation further supports the rational use of colistin as a
main factor in avoiding emergence of resistance.
The duration of colistin treatment is an important factor
in the emergence of resistance. Patients colonized by colis-
tin-resistant isolates had received signiﬁcantly longer colistin
treatment. In addition, patients with longer duration of ICU
admission were at increased risk, although this may reﬂect a
higher frequency of colistin use in patients with long ICU
admissions. This is in agreement with previous studies [8,13]
and indicates the need for constant evaluation of the dura-
tion of antimicrobial treatment.
In addition to the emergence of CRKP colonization and
infection, colistin treatment was associated with infection by
pathogens intrinsically resistant to colistin, including Proteus,
Serratia, Morganella and Providencia. Again the duration of
colistin administration was a signiﬁcant contributing factor.
Treating physicians need to be vigilant regarding the timely
recognition and treatment of superinfections by intrinsically
resistant pathogens in patients on colistin treatment.
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